secwatch.observer — SEC 8-K summary
======================================

Issuer:     JUPITER NEUROSCIENCES, INC. (JUNS)
CIK:        0001679628
Form:       8-K
Filed at:   2026-05-20T13:45:15+00:00
Accession:  0001493152-26-024547
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA
--------------------------------------------------------------------------------

- Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.
- Development milestones: $3.33M upon Phase 3 initiation and $20M on FDA approval.
- Commercialization milestones up to $93.33M at net sales thresholds of $333M, $1B, $2B; plus perpetual 3% royalty.
- 90-day exclusivity period; definitive agreement target within 90 days; reverse termination fee of $600K if not executed.
- Deal follows President Trump's April 18, 2026 Executive Order on psychedelic medicine; ALA-002 is an FDA-designated NCE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1679628/000149315226024547/0001493152-26-024547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1679628/000149315226024547/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer